These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 36635380

  • 21. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
    Ernst D, Williams BA, Wang XH, Yoon N, Kim KP, Chiu J, Luo ZJ, Hermans KG, Krueger J, Keating A.
    Blood Cancer J; 2019 Jan 15; 9(2):6. PubMed ID: 30647406
    [Abstract] [Full Text] [Related]

  • 22. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L.
    Mol Ther; 2017 Aug 02; 25(8):1933-1945. PubMed ID: 28479045
    [Abstract] [Full Text] [Related]

  • 23. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, Varadhan R, Koldobskiy MA, Bonifant CL.
    J Immunother Cancer; 2021 Dec 02; 9(12):. PubMed ID: 34896980
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
    Meyer JE, Loff S, Dietrich J, Spehr J, Jurado Jiménez G, von Bonin M, Ehninger G, Cartellieri M, Ehninger A.
    Oncoimmunology; 2021 Dec 02; 10(1):1945804. PubMed ID: 34290907
    [Abstract] [Full Text] [Related]

  • 25. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
    Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N.
    Haematologica; 2018 Aug 02; 103(8):1288-1297. PubMed ID: 29773600
    [Abstract] [Full Text] [Related]

  • 26. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
    Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M.
    Front Immunol; 2022 Aug 02; 13():880108. PubMed ID: 35615350
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B, Tumanut C, Li L, Corper A, Challa D, Chang A, Begum H, Farokhi E, Woods C, Fan X.
    MAbs; 2024 Aug 02; 16(1):2381261. PubMed ID: 39048914
    [Abstract] [Full Text] [Related]

  • 29. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Wang XY, Bian MR, Lin GQ, Yu L, Zhang YM, Wu DP.
    Eur J Haematol; 2024 Jan 02; 112(1):83-93. PubMed ID: 37712633
    [Abstract] [Full Text] [Related]

  • 30. Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia.
    Ma H, Yan Z, Gu R, Xu Y, Qiu S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J.
    Cancer Immunol Immunother; 2024 Nov 13; 74(1):20. PubMed ID: 39535595
    [Abstract] [Full Text] [Related]

  • 31. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.
    Mol Cancer Ther; 2018 Feb 13; 17(2):554-564. PubMed ID: 29142066
    [Abstract] [Full Text] [Related]

  • 32. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC, Kahler J, Piché-Nicholas N, Hu W, Thibault S, Jiang F, Leal M, Katragadda M, Maderna A, Dushin R, Prashad N, Charati MB, Clark T, Tumey LN, Tan X, Giannakou A, Rosfjord E, Gerber HP, Tchistiakova L, Loganzo F, O'Donnell CJ, Sapra P.
    Clin Cancer Res; 2021 Jan 15; 27(2):622-631. PubMed ID: 33148666
    [Abstract] [Full Text] [Related]

  • 33. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
    Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, Marklin M, Heitmann JS, Kauer J, Osburg L, Zekri L, Bühring HJ, Mueller S, Hörner S, Baeuerle PA, Michaelson JS, Jung G, Salih HR.
    J Immunother Cancer; 2022 Mar 15; 10(3):. PubMed ID: 35288466
    [Abstract] [Full Text] [Related]

  • 34. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M, Kafi Z, Ghazizadeh L, Kharazi S, Behdani M, Faraji F, Shokrgozar MA.
    Iran J Allergy Asthma Immunol; 2019 Oct 30; 18(6):679-687. PubMed ID: 32245312
    [Abstract] [Full Text] [Related]

  • 35. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK, Li G, Eleya S, Yang G, Vandavasi VG, Hatefi A.
    Front Immunol; 2022 Oct 30; 13():1039969. PubMed ID: 36685519
    [Abstract] [Full Text] [Related]

  • 36. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
    Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH.
    Br J Haematol; 2010 Sep 30; 150(5):574-86. PubMed ID: 20636437
    [Abstract] [Full Text] [Related]

  • 37. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
    Wang M, Wu H, Duan M, Yang Y, Wang G, Che F, Liu B, He W, Li Q, Zhang L.
    Life Sci; 2019 Sep 01; 232():116663. PubMed ID: 31323275
    [Abstract] [Full Text] [Related]

  • 38. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
    Zhou T, Chen ML, Zhang CY, Liu XY, Wang ZZ, Xing HY, Tang KJ, Tian Z, Rao Q, Wang M, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar 14; 45(3):225-232. PubMed ID: 38716593
    [Abstract] [Full Text] [Related]

  • 39. Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
    Aldoss I, Clark M, Song JY, Pullarkat V.
    Hum Vaccin Immunother; 2020 Oct 02; 16(10):2341-2348. PubMed ID: 32692611
    [Abstract] [Full Text] [Related]

  • 40. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S.
    Cytotherapy; 2020 Jul 02; 22(7):369-376. PubMed ID: 32303428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.